Kornimate/medical-research-clean huggingface dataset:
machine learning for early diagnosis of endometriosis(mlendo)

Conditions: Endometriosis; Pelvic Pain; Infertility, Female

Summary: the project aims to create a large prospective data bank using the lucy medical mobile application and collect and analyze patient profiles and structured clinical data with artificial intelligence. in addition, authors will investigate the association of removed or restricted dietary components with quality of life, pain, and central sensitization.

introduction: endometriosis is a complex and chronic disease that affects ∼176 million women of reproductive age and remains largely unresolved. it is defined by the presence of endometrium-like tissue outside the uterus and is commonly associated with chronic pelvic pain, infertility, and decreased quality of life. despite numerous proposed screening and triage methods such as biomarkers, genomic analysis, imaging techniques, and questionnaires to replace invasive diagnostic laparoscopy, none have been widely adopted in clinical practice. . despite the availability of various screening methods (e.g., biomarkers, genomic analysis, imaging techniques) that are intended to replace the need for invasive diagnostic laparoscopy, the time to diagnosis remains in the range of 4 to 11 years. aims: the project aims to create a large prospective data bank using the lucy medical mobile application and collect and analyze patient profiles and structured clinical data with artificial intelligence. in addition, authors will investigate the association of removed or restricted dietary components with quality of life, pain, and central sensitization. methods: a baseline and longitudinal questionnaire in the lucy app collects self-reported information on symptoms related to endometriosis, socio-demographics, mental and physical health, nutritional, and other lifestyle factors. 5,000 women with endometriosis and 5,000 women in a control group will be enrolled and followed up for one year. with this information, any connections between symptoms and endometriosis will be analyzed with machine learning. conclusions: authors can develop a phenotypic description of women with endometriosis by linking the collected data with existing registry-based information on endometriosis diagnosis, healthcare utilization, and big data approach. this may help to achieve earlier detection of endometriosis with pelvic pain and significantly reduce the current diagnostic delay. additionally, authors can identify nutritional components that may worsen the quality of life and pain in women with endometriosis; thus, authors can create evidence-based dietary recommendations. keywords: endometriosis, machine learning, non-invasive diagnosis, diet

Eligibility criteria:
inclusion criteria: * women in reproductive age * 5000 patients with endometriosis * 5000 patients without endometriosis exclusion criteria: * ongoing pregnancy * malignant condition of ovary/uterus/breast

Keywords: endometriosis infertility
the safety and efficacy of the buprenorphine transdermal delivery system in subjects with chronic back pain.

Conditions: Chronic Low Back Pain

Summary: the objective of this study is to assess the safety and efficacy of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system and hydrocodone/acetaminophen in subjects with chronic back pain. the double-blind treatment intervention duration is 56 days during which time supplemental analgesic medication (ibuprofen) will be provided to all subjects in addition to study drug.

buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain. transdermal systems may offer advantages over currently indicated oral products including ease and convenience of use, improved compliance, possible reduction in patient care, and prolonged and consistent delivery of drug.

Eligibility criteria:
inclusion criteria: * clinical evidence of chronic back pain related to intervertebral disc disease, nerve root entrapment, spondylolithesis, osteoarthritis, or other, similar nonmalignant conditions. * back pain treated with an opioid-containing analgesic at a dose equal to or less than the equivalent of 90 mg of oral morphine per day or 12 or fewer capsules or tablets of an opioid combination analgesic per day. exclusion criteria: * receiving opioids at an average daily dose of greater than 90 mg of oral morphine equivalents or patients receiving more than 12 tablets per day of short-acting opioid-containing products. * scheduled to have surgery (including dental) during the study period that involved the use of pre- and/or postoperative analgesics or anesthetics. other protocol-specific exclusion/inclusion criteria may apply.

Keywords: low back pain opioid transdermal
prophylaxis of ileostomy closure site hernia by placing mesh

Conditions: Loop Ileostomy Closure

Summary: design prospective , randomized, parallel phase iv. objectives main objective * evaluate the effectiveness of the placement of a resorbable mesh in the prevention of incisional hernia of the abdominal wall at the site of a loop ileostomy when it is "closed " to rebuild the intestinal transit. the effectiveness evaluation is done by tracking with scheduled patient visits for 12 months, assessing the physical examination the presence or absence of an incisional hernia and an abdominal tomography at the end of the 12 months . secondary objectives comparison of complications(morbidity and mortality) to assess safety and tolerability of the placement of the mesh described .

experimental: reinforcement with absorbable mesh closure of the ileostomy closure incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available gore® bio-a® tissue reinforcement prosthesis (w. l. gore \& associates, flagstaff, arizona, usa) mesh. the bio-a® prosthesis is inserted using a "sandwich" method between the edges of the incision and maintained in situ with a continuous polydioxanone (pds) suture following a suture length to wound length (sl:wl) ratio of 4:1.

Eligibility criteria:
inclusion criteria: * patients undergoing a loop ileostomy closure exclusion criteria: * patients under 18 * pregnancy and lactation * patients allergic to polyglycolic / trimethylene carbonate * carrier of prosthetic mesh in the ostomy * patients presenting midline hernia. * patients affected by inflammatory bowel disease

Keywords: loop ileostomy eventration
effects of strength exercise on fall risk in elderly with alzheimer's disease

Conditions: Alzheimer Disease; Dementia; Alzheimer's Type (Etiology); Fall Risk; Elderly; Resistance Training

Summary: interventional study to show the effects of strength exercise on fall risk in elderly with alzheimer's disease


Eligibility criteria:
inclusion criteria: * accept to participate in the study, through informed consent * subjects aged 60 or over with medical diagnosis of azlheimer´s disease * minimal physical and mental state to perform the cognitive tests and strength exercise routine exclusion criteria: * neurodegenerative disease other than alzheimer's disease * suffering from serious somatic or psychiatric illnesses * patients who have practiced strength exercise regularly

Keywords: alzheimer disease elderly exercise fall risk
assessment of arformoterol for chronic obstructive pulmonary disease (copd) using hyperpolarized 3he mri

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to determine efficacy of mr imaging with hyperpolarized helium-3 gas in copd patients both before and after treatment.

hyperpolarized helium lung imaging has already been tested and proven to be scientifically possible in patients with a number of pulmonary disorders. however there is limited data on the sensitivity of this imaging technique, which would be essential for clinical use. this study is a double blinded study with two cohorts, each cohort being made up of patients with confirmed diagnosis of copd. one group will receive a placebo while the other will receive treatment. a comparison of the data will resume once twenty patients have been consented and completed the study procedures.

Eligibility criteria:
inclusion criteria: * are male or female and are 50 years or older * consent from the patient * have been diagnosed with copd * must be able to hold their breath for up to 12 seconds * must have a baseline fev1 ≤ 80% of predicted but fev1 \> 0.70 l * must have a smoking history of 15 or more packs per year * must have a breathlessness severity of ≥ 2 on the medical research council dyspnea scale * must be able to safely discontinue their respiratory medications for at least 12 hours. exclusion criteria: * have any contraindications to an mr exam such as a pace-maker, metallic cardiac valves, magnetic material (i.e., surgical clips) implanted electronic infusion pumps or any other conditions that would preclude proximity to a strong magnetic field * are undergoing the mr exam in an emergency situation * are pregnant or become pregnant at any point within the study time. * people with psychiatric disorders will be excluded from the study. * are claustrophobic and can not tolerate the imaging. * uses supplemental oxygen * have life-threatening or unstable respiratory status within 30 days before screening * have a diagnosis of asthma and/or any chronic respiratory disease other than copd * have a lung resection greater than 1 full lobe * have coronary artery disease or congestive heart failure * are allergic to arformoterol or similarly related drugs. * are taking any of the drugs listed in the risks section and are unable to stop taking them.

Keywords: copd aformoterol helium hyperpolarized helium hyperpolarized noble gas mri
extension study of ra101495 for patients with pnh who have completed a zilucoplan (ra101495) clinical study

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Summary: the purpose of this study is to enable continued access to zilucoplan (ra101495) for patients with paroxysmal nocturnal hemoglobinuria (pnh) after they complete a zilucoplan clinical study.


Eligibility criteria:
inclusion criteria: * completion of a qualifying ra pharmaceuticals sponsored zilucoplan (ra101495) pnh study * evidence of ongoing clinical benefit in the opinion of the investigator exclusion criteria: * history of meningococcal disease * current systemic infection or suspicion of active bacterial infection
safety and tolerability of long-term administration of oros hydromorphone hci (slow release) in cancer pain

Conditions: Analgesics, Opioid; Pain

Summary: the primary purpose of this study was to characterize the pain control achieved with long-term repeated dosing of oros hydromorphone (slow release) in patients with chronic cancer pain and the secondary purpose was to characterize the effects of pain on the patients' quality of life with long-term, repeated dosing of oros hydromorphone (slow release) taken by patients with chronic cancer pain.

study do-118x was a phase-3, multicenter, open-label extension study in adult patients with cancer pain who had successfully completed study do-118 with dose-stable pain control taking at least 8 mg of oros hydromorphone (slow release) or its equivalent morphine sulfate sr (slow release) dosage. patients were started on the dose of oros hydromorphone equivalent to the opioid dose on which they had achieved dose-stable pain control in the sr (slow release) phase of study do-118. patients returned to their study clinic once a month for 1 year. dosage adjustments to study medications and breakthrough pain medication were permitted. oros hydromorphone hci (slow release) tablets in 8, 16, 32 and 64mg doses administered orally every 24 hours

Eligibility criteria:
inclusion criteria: * patients who have chronic cancer pain, and who have successfully completed the oros hydromorphone sr (slow release) study, do-118 * patients must have been in dose-stable pain control in the last two days of the slow release phase of the study * patients who require at least 8mg of oros hydromorphone slow release every 24 hours for the management of chronic cancer pain exclusion criteria: * pain which is not considered to be potentially responsive to opioids * gastrointestinal disease of sufficient severity to be likely to interfere with oral analgesia including: dysphagia, vomiting, no bowel movement or bowel obstruction due to impaction within the 5 days prior to the start of the trial, severe gut narrowing that may affect the absorption or transit of orally administered drugs, particularly the insoluble oros outer coating * any patient in whom the risks of treatment with hydromorphone outweigh the potential benefits. such risk categories include: raised intracranial pressure, hypotension, hypothyroidism, asthma, reduced respiratory reserve, prostatic hypertrophy, hepatic impairment, renal impairment, elderly and debilitated, convulsive disorders and addison's disease

Keywords: chronic cancer pain oros hydromorphone hci (slow release) long-term repeated dosing
pain during femoral sheath removal in patients undergoing percutaneous coronary intervenion

Conditions: Percutaneous Coronary Intervention; Virtual Reality; Nursing Caries; Cryotherapy; Pain Management

Summary: it is to examine the effect of virtual reality and ice application on the pain level due to femoral sheath extraction.

after obtaining the necessary permissions for the research, the patients who were followed up in the hemodialysis unit of x,y, z hospitals were randomly divided into three groups (virtual reality glasses application, ice application and control group). randomization: since the number of male and female patients was wanted to be kept equal, simple randomization would not be possible, so the stratified randomization method was used. patients were assigned to groups in equal numbers according to their femoral sheath sizes. in our clinic, size 6 and 7 femoral sheaths are applied to male patients, and number 6 femoral sheaths are applied to female patients. male patients were assigned to equal groups according to femoral sheath size 6 and 7. since pci is not performed in our clinic on weekends except for emergencies, data were collected during working hours during a five-day weekday period. the pain level of the patients was evaluated using a numerical rating scale; * before the femoral sheath extraction (pas1), * during the femoral sheathing (sdq2), * immediately after the femoral sheathing (sdq3), * 30 minutes after the femoral sheathing (sdq4) and * 1 hour after the femoral sheathing (sdq4). sdö5) was evaluated and recorded.

Eligibility criteria:
inclusion criteria: * intervention in the femoral region, * femoral sheath size is 6-7 fr, * presence of only one sheath in the femoral region, * no analgesics were administered before femoral sheath removal, * absence of serious bleeding and major hematoma in the femoral region, * being over 18 years of age, * no communication problems, * having a place and time orientation, * no dizziness, * not having any psychiatric disease, * no visual, auditory or mental problems, * no previously identified cold allergy, * being willing and willing to participate in the study, exclusion criteria: * serious bleeding and major hematoma development in the femoral region, * not applying intracoronary stent or coronary angioplasty after coronary angiography, * vital signs are abnormal enough to prevent intervention, * having visual, auditory and mental disabilities, * having a communication problem, * not being willing and able to participate in the study, * it is defined as wanting to withdraw from the study at any stage of the study or being excluded from the study by the researcher.

Keywords: percutaneous coronary intervention virtual reality pain management nursing ice application
assessing the effect of different grades of chondromalacia on static and dynamic balance using biodex balance system

Conditions: Chondromalacia Patella

Summary: the aim of this study is to investigate the effect of grades of chondromalacia on static and dynamic balance.

chondromalacia patellae is a very common disorder which is characterized by softening, swelling, fraying, fissuring, and erosion of hyaline cartilage overlying the patella. patellar chondromalacia could be observed as a cause of patellofemoral pain, as well as in patients with osteoarthritis, in patients with knee trauma, or even in asymptomatic patients. balance, as an essential function in human daily life and activities, can be defined as central nervous system input. postural control can be divided into static balance and dynamic balance; static balance controls the oscillation amplitude of the body, and dynamic balance uses the body's internal and external information to analyze factors that influence the stability of interference (such as walking, pushing and pulling),and to maintain postural control. the perfect combination of static and dynamic balance is key to normal activities of the human daily life. 100 patients, 80 with different grades of chondromalacia (grade i, ii, iii, iv) with 20 participants in each group and 20 healthy participants in the control group will be recruited for the study to assess the effect of different chondromalacia grades on static and dynamic balance.

Eligibility criteria:
inclusion criteria: 1. age ranged from 18 to 40 years old 2. groups include both males and females 3. patients with grade i, ii, iii and iv chondromalacia: confirmation of diagnosis by mri 4. bmi will be ranged from 19.0 to 29.0 5. patients with unilateral or bilateral chondromalacia. 6. chronic cases for more than 3 months. 7. positive sign of knee pain according to patellar grind test exclusion criteria: 1. patients have not undergone knee replacement. 2. patients have not done intra-articular injection in the affected knee for the past 3 months. 3. patients with rheumatoid arthritis or other inflammatory arthritis. 4. patients with vestibular disorders or neurological conditions.

Keywords: biodex balance system static and dynamic balance assessment of chondromalacia
gmall registry and collection of biomaterial: prospective data collection regarding diagnosis, treatment and outcome of adult acute lymphoblastic leukemia (all) patients and related diseases associated with a prospective collection of biomaterial

Conditions: Acute Lymphoblastic Leukemia; Leukemia; Non-Hodgkin's Lymphoma

Summary: the gmall registry serves the purpose of all research and quality assurance. the registry collects data about diagnostics, treatment and outcome of adult all patients in the clinical routine, whether or not the patient is treated within a clinical trial.


Eligibility criteria:
inclusion criteria: * acute lymphoblastic leukemia (all subtypes) if treated according to all protocols * other types of leukemia (nk cell lymphoma/leukemia, biphenotypic acute leukemia) if treated according to all protocols * non-hodgkin's lymphoma of following subtypes: burkitt lymphoma, b cell lymphoma, b- or t-lineage lymphoblastic lymphoma, anaplastic large cell lymphoma, other nhl) if treated according to b-all protocols * age minimum 18 yrs
hometech healthy lifestyle program for mothers with young children

Conditions: Overweight

Summary: about 17% of chinese american preschool children are obese, compared to 12.4%of all children from age three to five years residing in the us; the prevalence of obesity is expected to increase in the future. therefore, the proposed study will adapt a home-based and technology-centered childhood obesity prevention program for low-income chinese american mothers of children three to five years old. the aims of the study are to assess the feasibility of the intervention and estimate the effect sizes on children's and mothers' outcomes.

this study aims to adapt and implement a family-centered and technology-based intervention to prevent obesity in young chinese american children from low-income families with overweight mothers. the proposed study framework is based on the information motivation behavioral skills model, which includes the mothers' gained knowledge/information, increased personal and social motivators, and acquired behavioral skills towards behavioral changes. the intervention will be developed with a community advisory committee and validated for cultural appropriateness through a beta-testing process. the validated intervention will be implemented thereafter. eligible overweight mothers with young chinese american children (ages three to five years) will be recruited from local day care settings, low-income housing and head start programs to participate in the study. participants will be randomized into either the intervention (n=15) or control group (n=15). participants in the intervention group will receive the 8-week online interactive sessions and activities delivered through tablet computers. participants in the control group will receive general health promotion topics relevant to preschool-age children via mailing materials weekly for eight weeks.

Eligibility criteria:
inclusion criteria: * children: * must be between ages three and five * have a mother who identifies her child as chinese; * be healthy-defined as free of chronic or acute illness. * mothers: * must identify themselves as chinese * the primary provider of the child, * be able to speak and read chinese or english; * with a bmi \>= 23.0; * meet low-income requirements in the bay area. exclusion criteria: * have acute or chronic conditions that prevent performing daily activities

Keywords: overweight mother childhood obesity prevention chinese american
clinical outcomes for patients with renal cell carcinoma who received first-line sunitinib

Conditions: Metastatic Renal Cell Carcinoma

Summary: this is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mrcc) who received sunitinib as first-line treatment.

clear cell mrcc patients who initiated sunitinib as first-line treatment between 2010 and 2018 were identified from the imdc database. patients were classified as favorable, intermediate, or poor prognostic risk group according to imdc criteria. overall survival, time to treatment discontinuation, and physician-assessed tumor response were evaluated.

Eligibility criteria:
inclusion criteria: * diagnosed with mrcc * initiated treatment post mrcc diagnosis and received sunitinib as first-line therapy * age 18 years or over at the time of mrcc diagnosis * actively treated at an imdc clinical center exclusion criteria: * initiated first line sunitinib treatment before 2010 * had non-clear cell mrcc

Keywords: vascular endothelial growth factor (vegf) sunitinib